pharmaphorum11h
Grifols files drug for rare bleeding disorder in the US
Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which ...
Seeking Alpha29d
GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade
GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac ...
Reuters1mon
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
Dec 9 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple ...
STAT1mon
GSK myeloma medicine improves survival in trial, another step in the drug’s revival
LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...
FierceBiotech1mon
GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. The two-stranded collaboration will ...
ETF Daily News24d
GSK plc (NYSE:GSK) Receives $43.25 Consensus Target Price from Brokerages
In related news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was purchased at an average price of $8.00 per ...